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sons require correction of discrepancies among the trials
because differences in follow-up, comparator, endpoints
and population (i.e. reference risk) affect the NNT. 
OBJECTIVE: To examine use of the NNT to compare 
the medications for reducing cardiovascular risk that have
been introduced in the last decade and the modiﬁcations
required to ensure a balanced evaluation. 
METHODS: The literature from January 1, 1995 to
January 5, 2001 was comprehensively searched to iden-
tify relevant trials according to preset inclusion criteria.
The raw NNT (reciprocal of the rate difference) was cal-
culated using whatever data (event numbers, rates, rela-
tive risk, regression coefﬁcient) were extractable from the
papers. Differences in the populations studied, compara-
tor, length of follow-up and endpoints were addressed by
incorporating the data from each study in a model of car-
diovascular disease to derive a standardized NNT over
two years. 
RESULTS: 16 studies representing 22 therapeutic com-
parisons published since 1995 met the inclusion criteria.
The annual reference risk (in the control group) varied
from 2.4% to 14.8% and the follow-up time from 1 to
6.2 years. Only 2 studies used an active comparator.
Crude NNTs ranged from 9.2 for pravastatin (the older
subgroup in CARE) to 376 in quinapril (QUIET). The
corresponding standardized NNTs showed less variation
(10.3 to 85.5) and substantially changed the ranking of
therapies: clopidogrel’s (CAPRIE) NNT dropped 9-fold
and changed 13 places while trandolapril’s (TRACE)
increased 3-fold and went from second best to 16th. 
CONCLUSION: Despite advocacy by the evidence-based
medicine movement, crude NNTs cannot be used to
compare therapies as they reﬂect methodological dispar-
ities in the underlying trials. Using an NNT model allows
valid comparisons by standardizing the key parameters.
Doing so for cardiovascular therapies reveals much
smaller differences and considerably alters their ordering.
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OBJECTIVES: To compare the cost-effectiveness of the
vasodilator stress agents, adenosine and dipyridamole, in
subjects with known or suspected coronary artery disease
(CAD) undergoing technetium-99m sestamibi single
photon computed tomography (SPECT) imaging in a
prospective, randomized trial from a hospital perspective. 
METHODS: Direct medical costs (standardized to 2001
US dollars) of the vasodilator stress agents, adverse effects
and monitoring were included. To determine the 
effectiveness of adenosine and dipyridamole, the overall
accuracy of each agent was calculated as follows:
(number of true-positive results + number of true-
negative results)/(total number of tests), using cardiac
catheterization as the gold standard for comparison. 
The incremental cost-effectiveness ratio (ICER) was 
calculated as follows: (total cost of adenosine-total cost
of dipyridamole)/(overall accuracy of adenosine–overall
accuracy of dipyridamole). One-way sensitivity analysis
was conducted, varying the costs of adenosine, dipyri-
damole, adverse effects and monitoring. 
RESULTS: Baseline demographics, including gender, 
age, co-morbidities and number of diseased vessels were
similar between the groups (p > 0.05 for all comparisons).
With adenosine (n = 49) sensitivity, speciﬁcity and 
overall accuracy was 82% (32/39), 60% (6/10) and 78%
(38/49), respectively. The sensitivity, speciﬁcity and
overall accuracy for dipyridamole was 68% (34/50), 67%
(6/9) and 68% (40/59), respectively (p > 0.05 for all com-
parisons with adenosine). The incidence of adverse events
was 43% with adenosine and 12% with dipyridamole 
(p < 0.001). The mean cost of the vasodilator stress agent
was $154+/127 with adenosine and $10+/-2 with 
dipyridamole (p < 0.001). When the cost of adverse
effects and monitoring was included, the total cost rose
to $160+/-27 and $19+/-3 with adenosine and dipyri-
damole, respectively (p < 0.001). The ICER was $1,410
(sensitivity analysis: $1,390 – $1,676) for each additional
correctly identiﬁed case with adenosine. 
CONCLUSIONS: In a randomized trial of patients
referred for vasodilator stress using technetium-99m 
sestamibi SPECT imaging, data indicate that adenosine is
more expensive but more effective than dipyridamole in
CAD detection.
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OBJECTIVES: As pharmaceutical costs continue to esca-
late, formulary decisions for hospitals are emerging as a
key focus. We conducted a baseline analysis to determine
the current costs and clinical outcomes for patients who
undergo percutaneous transluminal coronary angioplasty
(PTCA) with Heparin at the Center, prior to implement-
ing a new anticoagulant, Bivalirudin. 
METHODS: Retrospective, observational, analysis of
patients discharged from the Washington Hospital Center
in 2000 undergoing PTCA. Inclusion criteria included all
patients who had an ICD-9 PTCA procedure code and 
a DRG PTCA code (112 or 116). There were approxi-
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mately 3400 cases in the study. Age (<65>), sex, urgency
of admission and four co-morbidities were selected a
priori for sub-group analyses; diabetes mellitus, acute MI,
renal failure and dysrhythmia. Charges were converted to
costs using the U.S. CMS cost-to-charge ratio of 0.3574.
Economic data and the rates of clinical outcomes were
drawn from the Center’s patient-level data. Multi-factor
regressions were conducted to determine the incremental
effects of the four co-morbidities. Statistical signiﬁcance
and conﬁdence intervals were calculated for each 
endpoint. 
RESULTS: Average costs from admit to discharge were
$7,642 in total and pharmacy was $525 (p value <.05).
The geometric mean outcome rates were: death 0.8%,
2nd MI following PTCA 2.4%, revascularization proce-
dures 3.2%, hemorrhage 8.7%, transfusion 3.4% and
thrombocytopenia 1.3%. The sub-group with the highest
costs and worst clinical outcomes were women, urgently
admitted, > 65 years old who had renal failure, acute MI,
or dysrhythmia, in descending impact. 
CONCLUSION: The analyses provide a baseline to assess
the future impact of a new medication on the formulary,
as well as a basis to evaluate a new business agreement.
The economic and clinical analyses will be repeated 
following the new medication’s usage, and will then be
evaluated by the Center’s healthcare personnel in a group
session.
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OBJECTIVES: Capecitabine-docetaxel (CD) combina-
tion therapy signiﬁcantly prolongs time to disease 
progression and overall survival, compared with 
docetaxel monotherapy (D). This study assessed the 
cost-effectiveness of CD versus D from perspective of 
a US health delivery organization. 
METHODS: The model is based on analyses of a 
2-armed, balanced, multicenter, randomized trial of 
CD compared with D for the treatment of advanced
anthracycline-pretreated breast cancer (n = 511). Mean
time to progression and mean survival were estimated
using Kaplan-Meier methods. Data were collected on hos-
pital resource use data, infusions, drug use, and number
of consultations. Adjustments for QoL and cost per unit
of resources were based on published data. The uncer-
tainty in the cost-effectiveness was estimated using Monte
Carlo simulation methods. 
RESULTS: CD resulted in longer mean duration of 
treatment (129 days) than D (98 days). Patients lived an
average of 80 days longer with CD and experienced 64
days longer progression-free survival. No signiﬁcant 
differences were observed in medication use and con-
sultations. Patients receiving CD had fewer treatment-
related hospitalization days (4.8 days versus 5.5 days per
patient). Because of the lower planned docetaxel dose in
the combination arm (75 vs. 100mg/m2), the cumulative
dose of docetaxel was 648mg in combination, compared
with 847mg in monotherapy. 93% of the acquisition cost
of capecitabine was offset by lower docetaxel costs for
total added costs of $1,341. Cost per quality-adjusted
year of life (QALY) gained with CD was $5,520. The 5th
and 95th percentiles of cost-effectiveness were $4,400
and $11,600, respectively. 
CONCLUSIONS: Combining capecitabine with doc-
etaxel is cost-effective compared with docetaxel
monotherapy in anthracycline-pretreated patients, by CD
signiﬁcantly prolonging time to progression and overall
survival and lowering treatment-related hospitalization
days. The results of the simulation analyses provide 
assurance that combination therapy is likely to be cost-
effective when applied to non-trial settings.
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OBJECTIVES: We performed a pharmacoeconomic 
evaluation of LHRH agonists (LAs) in treating metasta-
tic prostate cancer compared to standard care, as identi-
ﬁed in the literature and by clinical experts, including:
estrogens (DES), orchiectomy, antiandrogens (AAs), and
combinations therapy (LAs + AAs). 
METHODS: A Markov model was constructed to
perform a cost-utility analysis (CUA) over 5 years, from
a Canadian provincial healthcare payer perspective.
Treatment efﬁcacy was determined by meta-analysis of
published clinical data, and utilities were derived from the
literature. 
RESULTS: In the base case analysis, DES was least costly
($588) but also least effective (0.52 QALYs). Orchiec-
tomy ($830 for 0.92 QALYs), with an incremental 
cost-utility ratio of $615/QALY versus DES, dominated
LAs ($8,116 for 0.75 QALYs) and AAs ($4,108 for 
0.62 QALYs). Treatment with combination therapy was 
the most costly at $18,029 and the most effective 
(1.04 QALYs), with an expected incremental ratio
